Alkermes’ Schizophrenia Drug Meets Main Goal Of Late-Stage Study

Alkermes Plc said its experimental drug to treat the symptoms of schizophrenia met the main goal of reducing the severity of symptoms of the disease in a late-stage study. The company said it plans to submit a marketing approval application for the drug, aripiprazole lauroxil, to the U.S. Food and Drug Administration in the third quarter of 2014. This was reported by Reuters on April 8, 2014.

Contact information: Jennifer Snyder, Public Relations Manager, Alkermes Plc, 852 Winter Street, Waltham, MA 02451; 781-609-6166; E-mail: jennifer.snyder@alkermes.com; Website: https://www.alkermes.com . . .